Press Releases

ABAC AbYlink Acteon afabicin (Debio 1450) afabicin (Debio 1450) ABSSSI afabicin (Debio 1450) Bone & joint infections altis labs Antibody Drug Conjufates Aspen Award BC Platforms Biocartis Campus après-demain CARB-X Carbonex CDiff Challenge Debiopharm-Inartis Clinical Trials Coorpacademy CPP cyclosporin A Debio 0123 Debio 0228 Debio 025 Debio 0432 Debio 0507 Debio 0513 Debio 0517 Debio 0614 (istaroxime) Debio 0615 Debio 0617 Debio 0719 Debio 0824 Debio 0826 Debio 0827 Debio 0928 Debio 0929 Debio 0930 Debio 0931 Debio 0932 NSCLS Debio 0932 RCC Debio 1036 Debio 1124 Debio 1124 SCLC Debio 1141 Debio 1142 Debio 1143 Debio 1143 Head & neck cancer Debio 1143 NSCLC Debio 1143 Ovarian cancer Debio 1143 selected solid tumors Debio 1143 with pembrolizumab Debio 1144 Debio 1347 Debio 1348 Debio 1449 Debio 1453 Debio 1454 Debio 1454M Debio 1454S Debio 1460 Debio 1561 Debio 1562 Debio 4126 Debio 8206 SC Debio 8609 Sanvar Debio 9902 - ZT-1 Debiopharm Academy Debiopharm Chair in Family Philanthropy Debiopharm Life Sciences Award Debiovision Degraducer Dexa Medica Diagnoplex EPFL EPI-hNE4 FibroTrap Fosanis fuze Galiena Capital genepoc genialis Groupe Bertrand H3 Pharma Haut-Lac HES-SO Huperzine-A IDEAL Iktos Immunexpress InnoCentive JCA-Mauvernay Award Kaiku Health KeyLemon little green house MedaSystems Mekonos Moapar Multilink Muscular Dystrophy naratuximab emtansine (Debio 1562) NeoVacs Novadiscovery nucleai Oncolifestyle Oncology Chair oncomfort Oxaliplatin paper.li PLGA Prix Debiopharm/Valais revogene Skiioo Spinomix Strategikon Swiss Biotech Association Téléthon Tremelimumab Triptorelin VeriSIM Life VivoSense Wazoku WhiteLab Genomics xevinapant YonaLink

March 6, 2014

Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland)

March 6, 2014

Debiopharm Group™ and Yale University extend and broaden their collaboration for the discovery and development of MIF inhibitors to treat…

March 5, 2014

Immunexpress Closes USD 6 Million Financing Round led by Debiopharm Group™

February 14, 2014

Debiopharm Group™ to Acquire Affinium’s Antibiotic Clinical Assets and Platform to Identify and Develop Targeted Antibiotics

January 13, 2014

Debiopharm Group™ Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty

January 8, 2014

Spinomix announces a milestone payment from Debiopharm Group™ and the appointment of a new CEO

December 1, 2013

BPA Solutions get Investment funds to accelerate rapid growth and global expansion

October 24, 2013

Atheris and Debiopharm Group™ to collaborate for the lead optimization of Debio 0826 using a “Reverse-Discovery” strategy

October 22, 2013

Curis and Debiopharm Group™ Announce Initiation of Phase I Dose Finding Clinical Study with a Combination of HSP90 Inhibitor Debio…